Omeros Corporation is a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics, orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The Company markets OMIDRIA for use during cataract surgery or intraocular lens replacement. Its clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome, and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy and other renal diseases.


Type
Public
HQ
Seattle, US
Founded
1994
Size (employees)
154 (est)
Website
omeros.com
Omeros Corporation was founded in 1994 and is headquartered in Seattle, US
Report incorrect company information

Key People/Management at Omeros Corporation

Gregory A. Demopulos

Gregory A. Demopulos

Chairman and Chief Executive Officer
Steven Whitaker

Steven Whitaker

Chief Medical Officer
George A. Gaitanaris

George A. Gaitanaris

Chief Scientific Officer
Timothy M. Duffy

Timothy M. Duffy

Vice President, Business Development
Catherine A. Melfi

Catherine A. Melfi

Chief Regulatory Officer
Leonard Blum

Leonard Blum

Chief Business and Commercial Officer
Show more

Omeros Corporation Office Locations

Omeros Corporation has an office in Seattle
Seattle, US (HQ)
201 Elliott Ave
Show all (1)
Report incorrect company information

Omeros Corporation Financials and Metrics

Omeros Corporation Revenue

Omeros Corporation's revenue was reported to be $64.83 m in FY, 2017
USD

Net income (Q1, 2018)

(30.1 m)

EBIT (Q1, 2018)

(27.7 m)

Market capitalization (20-Jul-2018)

948 m

Closing stock price (20-Jul-2018)

19.6

Cash (31-Mar-2018)

1.2 m
Omeros Corporation's current market capitalization is $948 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

1.6 m539 k13.5 m41.6 m64.8 m

Revenue growth, %

(66%)2406%208%

Cost of goods sold

1 m1.4 m1.1 m

Gross profit

12.5 m40.2 m63.7 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

388 k3.2 m3.3 m7.4 m10 m11.3 m12.3 m17.2 m21.7 m

Cost of goods sold

11 k365 k248 k327 k327 k378 k271 k157 k184 k203 k

Gross profit

377 k2.8 m3 m7.1 m9.7 m10.9 m12 m17 m21.5 m

Gross profit Margin, %

97%89%92%96%97%97%98%99%99%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

1.4 m354 k1.4 m2.2 m3.4 m

Accounts Receivable

379 k392 k6.5 m14.6 m

Prepaid Expenses

251 k1.2 m1.9 m1.8 m

Inventories

337 k568 k472 k1.1 m443 k
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

1.4 m2.6 m601 k978 k4.6 m10.3 m1.3 m3.4 m1 m1.2 m

Accounts Receivable

538 k3.1 m2.5 m6.6 m8.8 m10.5 m13.5 m26.3 m24.6 m

Prepaid Expenses

1.8 m1.4 m1.4 m2.5 m2.3 m1.4 m3.3 m3.4 m5.7 m

Inventories

566 k633 k445 k2 m1.8 m1.4 m960 k905 k822 k247 k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(39.8 m)(73.7 m)(75.1 m)(66.7 m)(53.5 m)

Depreciation and Amortization

302 k326 k209 k300 k551 k

Inventories

(568 k)96 k(656 k)685 k

Accounts Payable

(1.2 m)4.2 m(319 k)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Net Income

(18.7 m)(35.3 m)(55.3 m)(20.5 m)(33.2 m)(47.1 m)(15.1 m)(29.4 m)(36.9 m)(30.1 m)

Depreciation and Amortization

55 k107 k161 k53 k122 k211 k115 k234 k378 k1.1 m

Inventories

(159 k)(1.5 m)(1.3 m)(924 k)168 k223 k306 k196 k

Accounts Payable

(1.9 m)(1.2 m)721 k1.3 m(268 k)(321 k)771 k8.4 m8.1 m
Show all financial metrics

Omeros Corporation Operating Metrics

FY, 2014FY, 2015FY, 2016

Patents (foreign)

41 55 63

Patents Pending (foreign)

66 72 73

Patents (US)

271 310 492

Patents Pending (US)

300 327 313
Show all operating metrics
Report incorrect company information

Omeros Corporation Online and Social Media Presence

Embed Graph
Report incorrect company information

Omeros Corporation Company Life and Culture

Report incorrect company information